Articles By Jack Cush, MD
Biosimilars Match Biologic Originators in Rheumatoid Arthritis
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Read Article
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Read Article
EULAR 2023 Notes from Milan (6.09.2023)
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Read Article
EULAR 2023 – Day 3 Report
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Read Article
EULAR 2023 – Day 2 Report
Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.
Read Article
EULAR 2023 – Day 1 Report
EULAR 2023 launched today to crowds of attendees. The opening Plenary session and presidential address by Dr.
Read Article
EULAR 2023: Featured Industry Presentations
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR
Read Article
Colchicine and the Risk of Knee and Hip Replacement
Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.
Read Article
Belimumab in Lupus Nephritis
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
Read Article
